ClinicalTrials.gg
CompletedNCT04625855Updated Nov 12, 2020

Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects

A Phase 1 interventional study of TBPM-PI-HBr in Healthy Volunteers, sponsored by Spero Therapeutics. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-12.

Sponsored by Spero Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2020, 6 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to determine the absorption, metabolism, and excretion of [14C]-TBPM-PI-HBr and to characterize and determine the metabolites present in plasma, urine, and where possible, feces in healthy male subjects following a single oral administration.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • pharmacokinetics
  • TBPM-PI-HBr
  • tebipenem
  • absorption
  • metabolism
  • excretion
03

In context

Lead sponsor

Spero Therapeutics is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 3 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males, of any race, between 18 and 55 years of age, inclusive.
  • between 18.0 and 32.0 kg/m2, inclusive, and a total body weight between 50 and 100 kg, inclusive at Screening.
  • Willing and able to provide written and comply with all study assessments, restrictions, and adhere to the protocol schedule.
  • Medically healthy with no medical history, or abnormalities in physical examination, laboratory variables, vital signs or at the time of screening and Check-in, as deemed by the Investigator (or designee).
  • Have suitable venous access for repeated blood sampling.
  • History of a minimum of 1 bowel movement per day.

Exclusion criteria

Exclusion Criteria

  • History or suspicion of routine or chronic drug or alcohol abuse or dependence within 2 years prior to Check-in.
  • Use of tobacco, nicotine, or nicotine-replacement products within 30 days prior to Check-in or planned use during the study.
  • Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  • Use/receipt of any prescription or nonprescription medication, herbal products, vitamins or vaccines within 14 days (or 5 half-lives whichever is longer) prior to Check-in, without prior approval from the Medical Monitor.
  • Donation of more than 500 mL of blood or plasma within 56 days prior to Check-in, or receipt of a blood transfusion within 1 year prior to Check-in.
  • Receipt of any other product or participation in another investigational clinical study that included drug treatment within 30 days, or 5 times the t1/2 of the investigational drug, whichever is longer.
  • Have previously completed or withdrawn from this study or any other study investigating TBPM-PI-HBr, and have previously received TBPM-PI-HBr.
  • Subjects with exposure to significant diagnostic or therapeutic radiation (e.g., serial X-ray, computed tomography scan, barium meal) or current employment in a job requiring radiation exposure monitoring within 12 months prior to Check-in.
  • Subjects who have participated in a radiolabeled drug study where exposures are known to the Investigator within the previous 3 months prior to admission to the clinic for this study or participated in a radiolabeled drug study where exposures are not known to the Investigator within the previous 6 months prior to admission to the clinic for this study. The total 12-month exposure from this study and a maximum of 3 other previous radiolabeled studies within 3 to 12 months prior to this study will be within the CFR recommended levels considered safe, per United States (US) Title 21 CFR 361.1.
  • Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    TBPM-PI-HBr

    Healthy subjects meeting eligibility criteria will receive a single dose of 600mg of TBPM-PI-HBr

    Drug: TBPM-PI-HBr

Interventions

  • TBPM-PI-HBr (3 x 200 mg tablets) once

    Also known as: TBPM-PI-HBr oral capsule

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of Tebipenem (TBPM) will be determined following administration of [14C]-TBPM-PI-HBr to healthy male subjects

    The primary PK outcome endpoints following oral administration of \[14C\]-TBPM-PI-HBr will be derived for TBPM in plasma (calculated from whole blood concentrations) based on the concentration-time profile

    Time frame: Day 1 to Day 5

  2. Total radioactivity will be determined following administration of [14C]-TBPM-PI-HBr to healthy male subjects

    The primary PK outcome endpoints following oral administration of \[14C\]-TBPM-PI-HBr will be derived for total radioactivity in whole blood and plasma based on the total radioactivity concentration-time profile

    Time frame: Day 1 to Day 5

Secondary outcomes

  1. Metabolite profiling and chemical structuring of metabolites in plasma, urine, and, where possible, feces will be determined after a single oral dose of [14C]-TBPM-PI-HBr

    The secondary metabolite outcome endpoints will be derived: * metabolic profile of TBPM-PI-HBr * metabolic profile of TBPM-PI-HBr

    Time frame: Day 1 to Day 5

  2. Metabolite profiling and chemical structuring of metabolites in plasma, urine, and, where possible, feces will be determined after a single oral dose of [14C]-TBPM-PI-HBr

    The secondary metabolite outcome endpoints will be derived: • identification of the structure of TBPM-PI-HBr metabolites

    Time frame: Day 1 to Day 5

  3. The safety and tolerability of a single oral dose of [14C]-TBPM-PI-HBr when administered to healthy male subjects.

    The secondary safety outcome measures for this study are as follows: • incidence and severity of AEs

    Time frame: Day 1 to Day 5

  4. The safety and tolerability of a single oral dose of [14C]-TBPM-PI-HBr when administered to healthy male subjects.

    The secondary safety outcome measures for this study are as follows: •incidence of laboratory abnormalities, based on hematology, clinical chemistry, coagulation, and urinalysis test results

    Time frame: Day 1 to Day 5

07

Study locations

1 site
  • Covance Clinical Research Unit, Inc.
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Oct 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2020
First posted
Nov 12, 2020
StartActual
Sep 30, 2020
Primary completionActual
Oct 16, 2020
CompletionActual
Oct 16, 2020
Last update
Nov 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04625855
Lead sponsor
Spero Therapeutics
Collaborators
Covance
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Sep 30, 2020
Primary completion
Oct 16, 2020
Completion
Oct 16, 2020
Last update
Nov 12, 2020

Study contacts

Irene Mirkin, MD
principal investigator · Covance Clinical Research Unit

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tebipenem

Start the discussion